DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
compose your message
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
MARAC Advisory Statement Regarding SCD Patients during the time of “Reopening” the U.S. Economy
May 14, 2020—On Thursday April 16, 2020, the U.S. Coronavirus Taskforce provided recommendations on reopening the economy, giving states specific metrics, policies, and benchmarks regarding case load, hospital preparedness and testing capability with the goal of reopening on May 1. In order to proceed through the entire process, states must complete a two-week pre-phase, and then complete a two-week gating period with no evidence of rebound infections between each of the phases.
During the first two phases, the taskforce recommended that all vulnerable individuals remain at home and that everyone should work from home if they are able to do so. It also concluded that employers should make special accommodations for vulnerable individuals at work if working from home is not possible. During the last phase, vulnerable individuals could resume working normally, with physical distancing while in public places.
It is the position of the Medical and Research Advisory Committee (MARAC) of the Sickle Cell Disease Association of America that patients with sickle cell disease are considered vulnerable individuals based on American Society of Hematology (ASH) COVID19 guidelines.
news & eventsPost Traumatic Stress Disorder – WebinarThe Sickle Cell Mental Health Initiative...
education & researchFDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDS) for COVID-19[3/19/2020] FDA is aware of news reports...
news & eventsInformation About COVID-19 for Sickle Cell Disease PatientsCOVID-19, short for coronavirus disease ...
videos & visualsLifestyle Adjustments During COVID-19 – SCDAAhttps://www.sicklecelldisease.org/wp-con...
videos & visualsYou Should Get a COVID-19 Vaccine – Japanesehttps://www.youtube.com/watch?v=W8i01thN...
education & researchSecure-SCD Registry, Surveillance Epidemiology of Coronavirus (COVID-19) Under Research ExclusionThis registry is designed to capture ped...
news & eventsWhat People With Sickle Cell Disease Need to Know About COVID-19People with sickle cell disease are at i...
send a message
Don’t forget to join the oneSCDvoice community!
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.